Metropolitan Life Insurance Company (MetLife)’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio OCDX Stock Details OCDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,001	Closed	-$149K	–	2471
2022 Q1	$149K	Sell	8,001 -23,760	-75%	-$428K	0.01%	963
2021 Q4	$679K	Buy	31,761 +1,837	+6%	+$36.2K	0.01%	1224
2021 Q3	$553K	Buy	+29,924	New	+$603K	0.01%	1390
2021 Q2	–	Sell	-25,101	Closed	-$484K	–	2928
2021 Q1	$484K	Buy	+25,101	New	+$442K	0.01%	1436

Other funds holding OCDX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s OCDX Position: Q2 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 8,001 shares — an estimated $149K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in OCDX in Q1 2021 and held it in 4 quarters. The position peaked at $679K in Q4 2021. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 8,001 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $149K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q1 2021 and held it in 4 quarters.
Metropolitan Life Insurance Company (MetLife)'s Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $679K in Q4 2021.
1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2022, filed 11 Aug 2022.